Boston starts MADIT-RIT pacemaker trial
This article was originally published in Clinica
Boston Scientific has initiated a clinical trial to determine the best use of implantable cardioverter defibrillators (ICDs) or cardiac resynchronisation therapy defibrillators (CRT-Ds). Called MADIT-RIT, the trial follows three previous landmark trials: MADIT, MADIT II and MADIT-CRT, which also assessed the devices. MADIT-RIT will enrol 1,500 patients and aims to establish the best programming strategy for minimising the occurrence of unnecessary shocks in patients with no history of cardiac arrest. Last month, the MADIT-CRT trial strongly backed CRT-D devices over ICDs in the treatment of mild heart failure patients (www.clinica.co.uk, September 2 2009).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.